Russell Dahl ’97, the CEO and founder of Neurodon Corporation, has received a $3 million grant from the National Institute on Aging of the NIH to advance the company’s small molecule therapeutics for Alzheimer’s disease. Dahl’s research has been continuously funded by the NIH since 2018. Neurodon’s small molecule therapeutics demonstrate the ability to protect neurons and improve learning and memory in preclinical animal models of the disease.